<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623025</url>
  </required_header>
  <id_info>
    <org_study_id>S245.3.125</org_study_id>
    <secondary_id>2007-005433-11</secondary_id>
    <secondary_id>00623025</secondary_id>
    <nct_id>NCT00623025</nct_id>
  </id_info>
  <brief_title>Creon in HIV Patients With Steatorrhea</brief_title>
  <official_title>Double-blind, Cross-over, Randomized, Placebo-controlled, Multi-center Study to Investigate the Effect of CreonÂ®25 000 on the Coefficient of Fat Absorption of HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of pancreatic enzymes on steatorrhea in HIV patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinued prematurely due to low enrollment
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of fat absorption (CFA)</measure>
    <time_frame>After 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool fat excretion</measure>
    <time_frame>After 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization (yes, no) of stool fat excretion, i.e. &lt; 7 g/day</measure>
    <time_frame>After 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (yes, no) with respect to stool fat excretion, i.e. improvement in stool fat excretion as compared to baseline</measure>
    <time_frame>After 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool weight</measure>
    <time_frame>After 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Steatorrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon 25000</intervention_name>
    <description>6 to 9 capsules Creon 25000 per day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 to 9 capsules placebo per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria HIV positive patients with clinically stable disease (Karnofsky
        Performance Status &gt; 40);

          -  Steatocrit &gt; 2 %;

          -  Females of child-bearing potential must have a negative pregnancy test during prestudy
             or the subject must be surgically sterile or be at least 1 year postmenopausal as
             judged by the investigator;

          -  Women of child-bearing potential must be using a medically acceptable method of birth
             control throughout the study

        Exclusion Criteria

          -  Known allergy to pancreatin or any history of abnormal drug reaction;

          -  Known diagnosis of pancreatic exocrine insufficiency due to e.g. chronic pancreatitis
             or cystic fibrosis or pancreatectomy;

          -  Intake of an experimental drug within four weeks prior to entry into the study;

          -  Alcohol abuse within the last six months;

          -  Suspected non-compliance or non-cooperation;

          -  Any other lack of fitness, in the investigator's opinion, to participate in or to
             complete the study;

          -  Patients with a stool fat excretion &lt;= 7 g/day according to van de Kamer during the
             run-in period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59364</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59363</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suntje Sander, Director Clinical Development</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Steatorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Steatorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

